Prevention of bone mineral loss in postmenopausal women by norethisterone.
The effect of norethisterone on bone mineral metabolism was examined in 43 postmenopausal women. A significant decline in serum calcium, phosphate, and alkaline phosphatase in urinary calcium/creatinine ratio and in tubular maximum reabsorption of phosphate was demonstrated. There was no alteration in urinary hydroxyproline/creatinine ratio. The bone mineral content measured over two years by single photon absorptiometry was compared in 20 patients receiving norethisterone and a matched control group receiving placebo. There was significant protection against bone loss in the norethisterone group.
D000469:Alkaline Phosphatase / Q000097:blood; D001842:Bone and Bones / Q000378:metabolism*; D002118:Calcium / Q000097:blood / Q000652:urine; D003404:Creatinine / Q000097:blood / Q000652:urine; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D007684:Kidney Tubules / Q000378:metabolism; D008593:Menopause; D008875:Middle Aged; D008903:Minerals / Q000378:metabolism*; D009640:Norethindrone / Q000494:pharmacology*; D010024:Osteoporosis / Q000517:prevention & control*; D010710:Phosphates / Q000378:metabolism; D013997:Time Factors
D008903:Minerals; D010710:Phosphates; D003404:Creatinine; D000469:Alkaline Phosphatase; D006909:Hydroxyproline; D002118:Calcium; D009640:Norethindrone